Clopidogrel pretreatment for percutaneous coronary intervention: Double, double, dose in trouble?

Circulation

Volumn 111, Issue 16, 2005, Pages 2019-2021

  Williams, David O ^a,b  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

Angioplasty; Clopidogrel; Editorials; Platelets; Trials

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBIN; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HIRULOG; TIROFIBAN;

DRUG ELUTING STENT; EDITORIAL; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PLATELET AGGREGATION INHIBITORS; PREMEDICATION; TICLOPIDINE;

EID: 17744370517     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000164395.80487.AF     Document Type: Editorial

References (15)

1. Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE, Schneider DJ. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation. 2002;104:181-186.
2. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk cornoary angioplasty. N Engl J Med. 1994;330:956-961.
3. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
4. Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot CF, Anderson KM, Califf RM. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1999:354:2019-2024.
5. O'Shea JD, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, Strony J, Tcheng JE. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stem intervention: The ESPRIT Trial: a randomized controlled trial. JAMA. 2001;285:2468-2473.
6. Topol EJ, Moliterno DJ, Herrmann, HC, Powers ER, Grines CL, Cohen, DJ, Cohen EA, Bertrand M, Neumann F, Stone GW, DiBattiste PM, Yakubov SJ, DeLucca PT, Demopoulos L. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemia events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
7. Patti G, Colonna G, Pasceri, V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation. 2005;111:2099-2106.
8. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet. 1998;352:87-92.
9. Topol EJ, Moliterno DJ, Herrmann, HC, Powers ER, Grines CL, Cohen, DJ, Cohen EA, Bertrand M, Neumann F, Stone GW, DiBattiste PM, Yakubov SJ, DeLucca PT, Demopoulos L. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemia events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
10. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman D, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA. 2004;292:696-703.
11. Sabatine MS, Cannon CP, Gibson M, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189.
12. Kastrati A, von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schömig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation. 2004;110:1916-1919.
13. Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann F, Bollwein H, Volmer C, Gawaz M, Berger PB, Schömig A; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment (ISAR-REACT) Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pre-treatment with clopidogrel. N Engl J Med. 2004;350:232-238.
14. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
15. Steinhubl SR, Darrah S, Brennan D, McErlean E, Berger PB, Topol EJ. Uses of antiplatelet agents during PCI: practical issues. Circulation. 2003;108(suppl IV):IV-374. Abstract.